Table 6.

Univariate and multivariate analysis of prognostic factors for overall survival

Variables	No. of patients	Univariate analysis	Multivariate analysis
		P-value	Relative risk(CI)	P-value
Age
≥ 62	20	0.0893
< 62	20
Sex
Male	26	0.5103
Female	14
Primary lesion-related factors
Tumor differentiation
Well-differentiated	18	0.5670
Others	17
Tumor depth
-MP	9	0.7037
SS(A)-	31
TNM stage
I/II	21	0.8033
III/IV	18
Venous invasion
(−)	13	0.0560
(+)	21
Lymph node metastasis
(−)	26	0.7551
(+)	13
Lymphatic invasion
(−)	7	0.2828
(+)	27
Locally recurrent lesion-related factors
Tumor size (maximal diameter)
< 34 (mm)	19	0.6026
≥ 34 (mm)	19
CEA (Pre-CRT)
< 5 (ng/ml)	15	0.9454
≥ 5 (ng/ml)	25
CEA (Post-CRT)
< 5 (ng/ml)	26	0.6716
≥ 5 (ng/ml)	14
Resection status
R0	36	0.0035	0.355 (0.084–1.501)	0.1590
R1	4
Pathologic tumor response
Responders (TRG1–TRG 2)	17	0.0411	0.576 (0.169–1.960)	0.3769
Nonresponders (TRG3–TRG 5)	23
Pre-SUV
Low	20	0.2012
High	20
Post-SUV
Low	20	0.0009	0.203 (0.053–0.774)	0.0195
High	20
∆SUV
Low	20	0.6765
High	20
DR
Low	20	0.1127
High	20

Abbreviations: MP muscularis propri, SS, subserosa, A, adventitia, TNM, tumor node metastasis, TRG, the Mandard tumor regression grade, SUV, standardized uptake value, Pre-SUV, SUVmax values on the initial scan, Post-SUV, SUVmax values on the post-CRT scan, ∆SUV, ∆SUV = Pre-SUV– Post-SUV, DR, decreasing rate: DR = ∆SUV/ Pre SUV × 100(%), CRT, chemoradiation therapy